New analysis of LIFE trial shows reduction of new-onset atrial fibrillation with losartan

A new analysis of the LIFE study has shown that losartan can reduce new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy. General practitioner Brian Crichton summarises this new analysis and explains how losartan might achieve these effects.